Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AIM ImmunoTech Inc AIM

Healthcare Biotechnology
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called... see more

Recent & Breaking News (NYSEAM:AIM)

Hemispherx Updates the Status of the Alferon® Manufacturing Facility

GlobeNewswire July 11, 2016

Hemispherx Biopharma Enters into Settlement Agreements Dismissing All Pending Shareholder Derivative Litigation, Resolving Disputes with Insurance Carriers, and Obtaining Commitments of $3.5 Million in Payments to Company

GlobeNewswire June 8, 2016

Jason Industries Announces Upcoming Investor Outreach Events

GlobeNewswire June 8, 2016

Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, “Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)” in Expert Review of Clinical Pharmacology

GlobeNewswire June 7, 2016

Hemispherx Biopharma Obtains a Comprehensive Carter Omnibus Assignment of Intellectual Property

GlobeNewswire June 6, 2016

Hemispherx Biopharma Renews Sales, Marketing, Distribution and Supply Agreement with GP Pharm

GlobeNewswire May 31, 2016

UPDATE -- Hemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe

GlobeNewswire May 24, 2016

Hemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe

GlobeNewswire May 23, 2016

Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2016

GlobeNewswire May 16, 2016

Hemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update on May 17, 2016

GlobeNewswire May 12, 2016

Hemispherx Biopharma Retains Huron Consulting Group to Support Partnering Strategy and Planning for Alferon® and Ampligen®

GlobeNewswire April 20, 2016

Hemispherx Biopharma Enters into Alfa-n3 Interferon Clinical Trial, Sales, Marketing, Distribution, and Supply Agreement with Saudi Arabia's Premier Pharma Company in Fight Against the Deadly MERS Disease

GlobeNewswire April 4, 2016

Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2015

GlobeNewswire March 29, 2016

Hemispherx Biopharma Announces Conference Call to Discuss Management Changes and Provide Corporate Update on March 30, 2016

GlobeNewswire March 22, 2016

Hemispherx Biopharma Reviews Ampligen® Data With National Institute of Neurological Disorders and Stroke (NINDS)

GlobeNewswire March 10, 2016

Hemispherx Biopharma, Inc. (NYSEMKTS: HEB) With New Management Comes New Opportunity

Accesswire March 2, 2016

Hemispherx Biopharma Management Team: Reflects Company's Aggressive Commitment to Strategies Designed to Reach Commercial Goals, Preserve Financial Capital, and Increase Stockholder Value

GlobeNewswire February 22, 2016

Hemispherx Biopharma Exploring Possible Research Programs in Zika Virus Modeled on a Prior Alferon® N Clinical Trial on Closely Related Flavivirus (West Nile)

GlobeNewswire February 9, 2016

Hemispherx Biopharma Introduces a Voluntary Stock Purchase Plan to Create Shareholder Value

GlobeNewswire February 3, 2016

Hemispherx Biopharma Europe N.V./S.A. : Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Alferon N Injection® as a Treatment of Middle East Respiratory Syndrome (MERS)

GlobeNewswire January 20, 2016